First Clinical Medical college, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Medicine (Baltimore). 2021 Dec 30;100(52):e28283. doi: 10.1097/MD.0000000000028283.
Central retinal vein occlusion (CRVO) is one of the most common retinal vascular diseases, which is closely related to systemic diseases like hypertension, diabetes and arteriosclerosis. Due of its blinding, it will seriously reduce the quality of life. Macular edema (ME) caused by CRVO is one of the serious complications of visual impairment. We found that the severity of ME in CRVO was positively associated with vascular endothelial growth factor (VEGF) in the anterior chamber. With the accelerated pace of modern life and the changed dietary structure, the incidence of this disease will continue to rise. Therefore, it is of great practical significance to seek effective treatment methods. Intraocular injection of anti-VEGF can effectively alleviate ME and improve visual acuity, showing excellent clinical application prospects. In recent years, there have been some new understandings and advances on the etiology and treatment methods of the present disease, such as the deepening into the molecular biology and gene level. Clinical studies on the efficacy of the disease have emerging. Therefore, a network meta-analysis (NMA) of anti-VEGF treatment for CRVO is particularly necessary to systematically compare its efficacy.
The two reviewers will comprehensively retrieved electronic databases such as PubMed, The Cochrane Library, Wanfang database, Web of Science, Chinese Scientifific Journals Database, EMBASE, China National Knowledge Infrastructure, and China BioMedical Literature. A randomized controlled trial for CRVO against VEGF between January 2010 and June 2021 was included according to the relevant content of the study. In addition, 2 researchers will screen the literature to assess the risk bias for the included articles. We will evaluate the collected evidence and data using a Bayesian NMA method, and analyzed it with STATA and WinBUGS software.
Anti-VEGF is one of the effective methods for ME in CRVO patients, accordingly, this study will evaluate its efficacy and safety using a Bayesian NMA system.
This study can provide an effective rationale for the clinical application of anti-VEGF for CRVO, contribute to the treatment of CRVO and patient condition rehabilitation in clinical work.
Do not require.
INPLASY2021110073.
视网膜中央静脉阻塞（CRVO）是最常见的视网膜血管疾病之一，与高血压、糖尿病和动脉硬化等系统性疾病密切相关。由于其致盲性，严重降低了生活质量。CRVO 引起的黄斑水肿（ME）是视力损害的严重并发症之一。我们发现，CRVO 中的 ME 严重程度与前房中的血管内皮生长因子（VEGF）呈正相关。随着现代生活节奏的加快和饮食结构的改变，这种疾病的发病率将继续上升。因此，寻求有效的治疗方法具有重要的现实意义。眼内注射抗 VEGF 可有效缓解 ME 并提高视力，显示出极好的临床应用前景。近年来，对本病的病因和治疗方法有了一些新的认识和进展，如深入到分子生物学和基因水平。对本病疗效的临床研究也层出不穷。因此，对 CRVO 抗 VEGF 治疗进行网络荟萃分析（NMA），特别有必要系统比较其疗效。
两位审稿人将全面检索 PubMed、The Cochrane Library、万方数据库、Web of Science、中国科学引文数据库、EMBASE、中国知网和中国生物医学文献数据库等电子数据库，纳入 2010 年 1 月至 2021 年 6 月期间针对 CRVO 对抗 VEGF 的随机对照试验。此外，2 位研究者将筛选文献以评估纳入文章的偏倚风险。我们将使用贝叶斯 NMA 方法评估收集的证据和数据，并使用 STATA 和 WinBUGS 软件进行分析。
抗 VEGF 是治疗 CRVO 患者 ME 的有效方法之一，因此，本研究将使用贝叶斯 NMA 系统评估其疗效和安全性。
本研究可为 CRVO 抗 VEGF 的临床应用提供有效依据，有助于临床工作中 CRVO 的治疗和患者病情的康复。
不需要。
INPLASY 注册号：INPLASY2021110073。
